Details
Stereochemistry | MIXED |
Molecular Formula | C18H22N2O5S |
Molecular Weight | 378.443 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(CC)OC3=CC=CC=C3)C(O)=O
InChI
InChIKey=HOCWPKXKMNXINF-XQERAMJGSA-N
InChI=1S/C18H22N2O5S/c1-4-11(25-10-8-6-5-7-9-10)14(21)19-12-15(22)20-13(17(23)24)18(2,3)26-16(12)20/h5-9,11-13,16H,4H2,1-3H3,(H,19,21)(H,23,24)/t11?,12-,13+,16-/m1/s1
Propicillin (Baycillin Mega) is this semisynthetic penicillin, analogous to penicillin V, was introduced in the early 1960s. Although it is better absorbed from the gastrointestinal tract, overall it is inferior to phenoxymethylpenicillin and phenoxyethylpenicillin because of its lower antibacterial activity. Propicillin is used by propicillin-susceptible pathogens in adults and adolescents from 14 years to treat mild to moderate bacterial infections. These include skin infections, ear, nose and throat infections (such as otitis media, sinusitis, tonsillitis, pharyngitis) and infections of the bronchi andlung inflammation. Moreover propicillin can for prevention and treatment of scarlet fever or against rheumatic fever are used (bacterial infection of the nose and throat). Even with tooth or jaw surgery the drug is used to treat an endocarditis endocarditis prevent. Its mechanism of action could be due to binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, thus propicillin may inhibit the third and last stage of bacterial cell wall synthesis
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: penicillin-binding proteins of bacterial cell Sources: http://www.ncbi.nlm.nih.gov/pubmed/7194084 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Unknown Approved UseUnknown |
|||
Curative | Baycillin Mega Approved Useto reat mild to moderate bacterial infections. These include skin infections, ear, nose and throat infections (such as otitis media , sinusitis, tonsillitis , pharyngitis) and infections of the bronchi and lung inflammation. |
|||
Curative | Baycillin Mega Approved Useto reat mild to moderate bacterial infections. These include skin infections, ear, nose and throat infections (such as otitis media , sinusitis, tonsillitis , pharyngitis) and infections of the bronchi and lung inflammation. |
|||
Curative | Baycillin Mega Approved Useto reat mild to moderate bacterial infections. These include skin infections, ear, nose and throat infections (such as otitis media , sinusitis, tonsillitis , pharyngitis) and infections of the bronchi and lung inflammation. |
|||
Curative | Baycillin Mega Approved Useto reat mild to moderate bacterial infections. These include skin infections, ear, nose and throat infections (such as otitis media , sinusitis, tonsillitis , pharyngitis) and infections of the bronchi and lung inflammation. |
|||
Curative | Baycillin Mega Approved Useto reat mild to moderate bacterial infections. These include skin infections, ear, nose and throat infections (such as otitis media , sinusitis, tonsillitis , pharyngitis) and infections of the bronchi and lung inflammation. |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6421744
Curator's Comment: http://www.ncbi.nlm.nih.gov/pubmed/4967932
1 Mega unit (0.7 g) propicillin orally as oblong tablets one or two hours before surgery
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/827661
Unknown
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
J01CE03
Created by
admin on Fri Dec 15 16:19:57 GMT 2023 , Edited by admin on Fri Dec 15 16:19:57 GMT 2023
|
||
|
WHO-VATC |
QJ01CE03
Created by
admin on Fri Dec 15 16:19:57 GMT 2023 , Edited by admin on Fri Dec 15 16:19:57 GMT 2023
|
||
|
NCI_THESAURUS |
C1500
Created by
admin on Fri Dec 15 16:19:57 GMT 2023 , Edited by admin on Fri Dec 15 16:19:57 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL2105612
Created by
admin on Fri Dec 15 16:19:57 GMT 2023 , Edited by admin on Fri Dec 15 16:19:57 GMT 2023
|
PRIMARY | |||
|
1345
Created by
admin on Fri Dec 15 16:19:57 GMT 2023 , Edited by admin on Fri Dec 15 16:19:57 GMT 2023
|
PRIMARY | |||
|
m9201
Created by
admin on Fri Dec 15 16:19:57 GMT 2023 , Edited by admin on Fri Dec 15 16:19:57 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000081175
Created by
admin on Fri Dec 15 16:19:57 GMT 2023 , Edited by admin on Fri Dec 15 16:19:57 GMT 2023
|
PRIMARY | |||
|
SUB10106MIG
Created by
admin on Fri Dec 15 16:19:57 GMT 2023 , Edited by admin on Fri Dec 15 16:19:57 GMT 2023
|
PRIMARY | |||
|
34649
Created by
admin on Fri Dec 15 16:19:57 GMT 2023 , Edited by admin on Fri Dec 15 16:19:57 GMT 2023
|
PRIMARY | RxNorm | ||
|
208-995-5
Created by
admin on Fri Dec 15 16:19:57 GMT 2023 , Edited by admin on Fri Dec 15 16:19:57 GMT 2023
|
PRIMARY | |||
|
DTXSID3046291
Created by
admin on Fri Dec 15 16:19:57 GMT 2023 , Edited by admin on Fri Dec 15 16:19:57 GMT 2023
|
PRIMARY | |||
|
551-27-9
Created by
admin on Fri Dec 15 16:19:57 GMT 2023 , Edited by admin on Fri Dec 15 16:19:57 GMT 2023
|
PRIMARY | |||
|
92879
Created by
admin on Fri Dec 15 16:19:57 GMT 2023 , Edited by admin on Fri Dec 15 16:19:57 GMT 2023
|
PRIMARY | |||
|
8X1R260V33
Created by
admin on Fri Dec 15 16:19:57 GMT 2023 , Edited by admin on Fri Dec 15 16:19:57 GMT 2023
|
PRIMARY | |||
|
2297
Created by
admin on Fri Dec 15 16:19:57 GMT 2023 , Edited by admin on Fri Dec 15 16:19:57 GMT 2023
|
PRIMARY | |||
|
C66483
Created by
admin on Fri Dec 15 16:19:57 GMT 2023 , Edited by admin on Fri Dec 15 16:19:57 GMT 2023
|
PRIMARY | |||
|
C100135
Created by
admin on Fri Dec 15 16:19:57 GMT 2023 , Edited by admin on Fri Dec 15 16:19:57 GMT 2023
|
PRIMARY | |||
|
PROPICILLIN
Created by
admin on Fri Dec 15 16:19:57 GMT 2023 , Edited by admin on Fri Dec 15 16:19:57 GMT 2023
|
PRIMARY | |||
|
DB13660
Created by
admin on Fri Dec 15 16:19:57 GMT 2023 , Edited by admin on Fri Dec 15 16:19:57 GMT 2023
|
PRIMARY | |||
|
52429
Created by
admin on Fri Dec 15 16:19:57 GMT 2023 , Edited by admin on Fri Dec 15 16:19:57 GMT 2023
|
PRIMARY | |||
|
52427
Created by
admin on Fri Dec 15 16:19:57 GMT 2023 , Edited by admin on Fri Dec 15 16:19:57 GMT 2023
|
PRIMARY |
ACTIVE MOIETY